11^th World Congress on

Biosimilars and Biologics

Biosimilar 2019

Theme: Biosimilars Vs. Biologics: Does accessibility ensure efficiency?

Meetings International welcomes every one of the members, experts of pharmacy, biopharmaceuticals, professors, analysts, delegates, students, business specialists and authorities from wherever all through the globe at "11th World Congress on Biosimilars and Biologics" in Miami, USA, which incorporates keynote sessions, oral talks, poster sessions distribution features, exhibition and workshops. Biosimilar 2019 is an international platform to discuss the discoveries, new developments and scopes of biologics & biosimilars.

After the successful completion of Biosimilar 2018 with the greetings of Dr. Sarfaraz K Niazi, Karyo Biologics LLC and Pharmaceutical Scientist Inc, USA, on August 20-21, 2018 at Chicago, USA; we are organizing our Biosimilar 2019 and we need your valuable suggestion and support.

Scientific Sessions:

Track 1. Biologics & Biosimilars Analytical Strategies:

Analysis of biosimilars and biologics forms to be one of the most important aspects towards the biologics and biosimilar development process. Biosimilars analytical methods for process development and validation as well as use of production technologies such as disposables and supply chain logistics can help companies establish facility flexibility.

This biosimilars global event also includes Bio analytical methods, Formulation, Bioassay for comparability and potency testing, GMP protein analysis, LC/MS analysis for discovery, preclinical, and clinical programs.

Related Conferences: European Biosimilars Congress, April 26-27, 2018 Rome, Italy; 13th International Conference on Biologics and Biosimilars, October 24-25, 2018 Boston, USA; 9th Asian Biologics and Biosimilars Congress, August 20-21, 2018 Tokyo, Japan; International Conference & Exhibition on Biologics and Biosimilars, Orlando, Florida, USA; Biologics & Biosimilars Congress, March 26-27, 2018, Berlin, Germany.

Track 2. Biologics VS Biosimilars:

Development of biologics is considerably more expensive and time-consuming than that of small molecules. The latter contain only carbon, oxygen and nitrogen, which are easier to synthesize with low batch-to-batch variability

Despite the high cost of development, due to their targeted nature with high efficacy, biologics are now taking on an increasingly important role in the treatment of common and/or serious diseases.

To be called a biosimilar, these compounds need to demonstrate structural and functional similarities with comparable pharmacokinetic and pharmacodynamics properties to the originator compounds using sensitive indicators, for example, levels of cytokines, blood glucose or white cell counts.

Once approved, the inherent nature of these complex molecules calls for continuing surveillance to detect allergic reactions or rare events due to immunogenicity or other untoward reactions, which may not be detectable during the development stage. Besides, the batch-to-batch variations may also lead to efficacy and safety issues in the post marketing phase.

Track 3. Biosimilars VS Bio betters:

Some evidence points to the fact that the first biosimilars were not as good as their branded counterparts. Whereas in case of Bio betters gain in effectiveness may come with a larger price tag, as the drug would be touted as an improvement on the current standard of treatment, and not a direct competitor in the market. This does nothing to help the cost-conscious consumer looking for cheaper alternatives. Now the question arise Biosimilars or Bio better? Accessibility & similarity or efficacy & improvement what will you choose?

Track 4. Biosimilars in Oncology and rare diseases:

Over the past two decades, the United States and Europe experienced a dramatic and unsustainable rise in cancer health care costs. Eight of the top ten most expensive drugs are cancer drugs, notably the novel biologic agents arising out of the recent revolution in our understanding of the genetic and molecular basis of malignancy.

The demonstration of comparable efficacy and safety to the originator is a challenge for both regulators and companies, necessitating careful pharmacovigilance following approval.

Track 5. Statistical approaches to quality comparability:

FDA’s guidance on comparability protocols discusses the need and considerations for assessing any product or process change that may impact safety or efficacy of a drug product or drug substance. Areas to consider may include:

• Changes to the manufacturing process

• Changes to the analytical procedure or analytical method

• Changes in manufacturing equipment

• Changes in location or manufacturing facilities

• Changes to container closure systems

• Changes in materials, concentrations, and/or formulation

• Changes in process analytical technology (PAT) or process controls

• Any change that may influence safety or efficacy of the product.

Generally, a comparability protocol includes an analytical method(s), a study design, a representative data set, and associated acceptance criteria. The defined protocol is used to demonstrate comparability. There are typically two types of data analysis techniques that are used: statistical significance and practical significance or equivalence. In the case of statistical significance, the differences are always considered to be zero. In the case of practical significance, they are not considered to be zero; however, they are considered to be so small that they are considered to be practically zero. Often, testing using statistical significance (zero change) may result in the detection of real differences that are not practically meaningful and do not identify practically meaningful differences in the product.

Track 6. Bioequivalence Assessment for Biologics & Biosimilars:

Bioequivalence focuses on the equivalence of release of the active pharmaceutical ingredient from the pharmaceutical product and its subsequent absorption into the systemic circulation. This session has utmost importance in context to the fact that only a suitably bioequivalent drug candidate that conforms the results in all respects to the original licensed product can be called as biosimilar drug.

Of all attempts towards developing a follow on biologics or a biosimilar drug the main detection point stands at the bioequivalence assessment. Once the bioequivalence has been obtained it can be 70% ascertained the drug qualifies to be a suitable biologics or biosimilars.

Track 7. Generics and Biosimilars: Industrial Strategy and Market Analysis:

Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to enter the biosimilars market: research and development, manufacturing, supporting activities, marketing, and lobbying. Understanding the importance of each of these capabilities will be key to maximizing the value generated from the biologics patent cliff.

This biosimilars conference will look at the facets of current challenges in biosimilar development. This biosimilar conference will focus on multiple aspects of biosimilar product development to successfully deliver safe, potential and efficacious biologic products to the market.

Track 8. Clinical trials of Biologics & Biosimilars:

Biologic trials require a customized approach based on the therapeutic indication and study specific goals. The CRO must work with the sponsor to develop an effective plan and execution strategy for these study types that includes subject recruitment, regulatory, clinical safety monitoring, specialized pharmacy expertise, and bio analytical support while ensuring subject safety throughout the entire trial. This is best accomplished with a detailed risk assessment to ensure all the bases are covered. The risk assessment isn’t just done once and then forgotten, but is a living document that is updated as new information about the molecule is gathered.

Track 9. Intellectual Property Rights and Regulatory Approaches for Biosimilars:

The EU has pioneered the development of a regulatory system for biosimilar products. To date the EMA has approved nineteen biosimilars for use in the EU including the recent landmark approval of monoclonal antibodies.

The US biosimilar pathway was signed into law in March 2010 as part of the Affordable Care Act. The US Food and Drug Administration (FDA) issued three draft guidance documents in February 2012 on biosimilar product development to assist industry in developing such products in the US. As these regulations will undergo further review and revision by the FDA, the US remains behind the EU, Latin America and Asia in terms of biosimilar drug development and commercialization.

The Biologics Price Competition and Innovation Act (BPCIA) opened the door for companies to seek FDA approval to manufacture and sell biosimilar or interchangeable versions of brand name biological products. The BPCIA also provides reference product sponsors with 12 years of market exclusivity, but unlike the Hatch-Waxman Act, it does not require reference product sponsors to list patents in an Orange Book equivalent and does not include an automatic 30-month stay of FDA approval upon the timely filing of a lawsuit. The BPCIA, however, does provide pre-litigation procedures for the parties to follow, including identification of relevant patents and each party’s basis for infringement and invalidity.

Track 10. GMP, GCP, QC & R&D:

Good Manufacturing Practice is that part of quality management which ensures that products are consistently produced and controlled according to the quality standards appropriate to their intended use and as required by the marketing authorization, clinical trial authorization or product specification. Good Manufacturing practices aims at both production and Quality Control. Fact about Current Good Manufacturing Practices (cGMP) is aimed primarily at managing and minimizing the risks inherent in pharmaceutical manufacture to ensure the quality, safety and efficacy of products. Over the previous decade, a developing offer of the business' R&D yield has comprised of incremental enhancements to existing generic medications instead of new sub-atomic substances. Execution measures that consider just altogether new medications, for example, the quantity of NME endorsements every year miss that move and underestimate the business' R&D Field

Track 11. Current Challenges in development of Biosimilars:

Over the past ten years, regulatory authorities worldwide have been focusing on developing guidelines for biosimilars. However, until a global development strategy is adopted, regulatory, therapeutic and legal challenges remain. While the prospect of cost savings and efficiency make the biosimilar market attractive, companies and their outsourcing partners planning to enter this market must be aware of current regulations and issues in the global marketplace and be prepared to respond quickly to changes.

As global regulations and guidelines progress, questions such as the following are broadly being debated in the pharmaceutical industry:

Should interchangeability and automatic substitution be allowed?
Should biosimilars have the same international non-proprietary name as the reference product?
How much longer will patent litigation hinder the U.S. market?

In countries without biosimilar guidelines, interaction with regulators can be challenging. It is advisable to approach agencies proactively for scientific advice to avoid potential questions and delays in clinical trial approval. In most cases, reviewers need to be guided through the FDA, EMA and PMDA (Japan) guidelines. This is important in order to receive agency validation of the development program, discuss issues, identify gaps in the submission package, review the protein characterization steps conducted, agree on the source of the reference product and familiarize the assessors with the biosimilar product before submitting clinical trial applications.

Market Research Report

Introduction:

The global biosimilars market is expected to reach USD 10.90 Billion by 2021 from USD 3.39 Billion in 2016, at a CAGR of 26.3% during the forecast period. The major factors driving the growth of this market are the increasing demand for biosimilar drugs due to their cost-effectiveness, growing pressure to curtail healthcare expenditure, rising geriatric population, strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars, and increasing government support and initiatives to develop and promote biosimilars.

On the basis of product,

The biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. In 2018, the recombinant non-glycosylated proteins segment is expected to account for the largest share of the market. New product launches, cost-effectiveness, growing incidence of diabetes, and presence of many biosimilar versions of insulin in the pipeline are the factors driving the growth of this segment.

Based on manufacturing type

The biosimilars market is segmented into in-house manufacturing and contract manufacturing organizations. In 2018, the contract manufacturing segment is expected to account for the largest share of the market

Based on application, the biosimilars market is segmented into oncology, blood disorders, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other applications. The oncology segment is expected to grow at the highest CAGR during the forecast period. The rising incidence of cancer, high cost of biologics, pressure to reduce healthcare expenditure, and low cost of biosimilars are factors contributing to the growth of this segment.

Based on region, the global biosimilars market is segmented into North America, Europe, Asia, and RoW. Asia is expected to grow at the highest CAGR during the forecast period. This can be attributed to factors such as the low per capita consumption, rapid growth in economies, rise in technological innovation, trade links, and the rise in medical tourism.

The key players in the biosimilars market include Pfizer Inc. (U.S.), Sandoz International GmbH (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Amgen Inc. (U.S.), Biocon Ltd. (India), Dr. Reddy’s Laboratories (India), F. Hoffmann-La Roche Ltd. (Switzerland), Celltrion Inc. (South Korea), and Samsung Bioepis (South Korea).

American Market: USA is a largest market of biologics globally. With the approval of the first biosimilar in the U.S in early 2015 and the expected patent expiration of 12 biologics by 2020, biosimilars are expected to competitively penetrate the biologic's market.

In 2010, patient care act was passed by Obama which give licensure pathway for interchangeable products, which provided under the part of Biologics Price Competition and Innovation Act for the product demonstrating as biosimilar, manufacturers need to submit

Biologics License Application (BLA). Target reference products for the USA market are Monoclonal Antibodies (MAbs), recombinant protein and some high-purity protein products, out of which recombinant therapeutic with large market (sales) even with small profitable amount.

Biosimilar market is expected to represent CAGR of 62.2 % as the chances of growth of biosimilar market from $1.7 billion in 2014 to $30 billion by 2020.

Biosimilars will account for 4% to 10% of the biologics market total by 2020, depending on the number of biosimilars launched in the U.S. The U.S. is the largest market for biologics and the biosimilars can achieve 10% of the global sales in 2020, only if the volume growth for biologics is achieved in the U.S. market.

The main players looking to penetrate the US biosimilar market are currently Amgen, Mylan, Pfizer, Sandoz and Hospira.

Global Biosimilar Market

While the U.S. has approved only one biosimilar therapeutic; Japan, Australia and Europe have approved six, eight and 19 biosimilars respectively. Already, biosimilars have an exemplary safety track record in the E.U., Japan, and Canada where biosimilars are regularly competing against biologics for nearly seven years. The E.U. was the first geographic market to develop the process of authorization of biosimilars, setting an example for many other developing markets to follow suit. As of 2015, the E.U. has approved 19 biosimilars, out of 21 submissions, mostly for three reference biologics such as Somatropin, Epoetin alfa and Filgrastim.

Biosimilars generated revenues of $1.1 million in 2007 and gradually rose to $86.9 million in 2014. During this period, the market penetration of biosimilars in Europe and emerging markets was only about 8%. The top five biologics targeted most by biosimilar developers are Avastin, Enbrel, Herceptin, Humira and Rituxan, which together generate revenues of about $50 billion annually.

Biosimilar market in Europe:

Patent expiration and increased use of traditional generic drugs are leading to a shift of focus in the pharmaceutical industry toward investment in specialty drugs and high growth areas such as biosimilars in Europe. patent expiry of key product classes and a growing emphasis on cost effectiveness are making governments switch to affordable alternatives.

The EMA approved four additional biosimilars in 2016, including three biosimilars in two new product classes: a biosimilar of Amgen’s Enbrel (etanercept) and two biosimilars of Sanofi’s Clexane (enoxaparin sodium). Etanercept is a fusion protein used to treat a variety of autoimmune disorders and enoxaparin sodium is a low-molecular weight heparin indicated for preventing blood clots. These additional approvals bring the total of currently authorized biosimilars in Europe to 22 and the product classes to eight

It was estimated that in 2015, Europe accounted for the largest market share of the global biosimilars market, followed by Asia Pacific.here is thus a tremendous opportunity for biosimilar manufacturers. However, the development of biosimilar drugs is riddled with complexities, from R&D to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry.

About 30 companies are actively developing biosimilar medicines and are researching on the biosimilar versions of 16 distinct molecules that will lead to greater competition by 2020, with 8 major biologic medicines expected to lose exclusivity by 2020.

The next five years are going to be an interesting period in the biosimilars market as a number of biologic drugs are going to lose their exclusivity.

Asia pacific: Asia-Pacific is the fastest growing market for biosimilars because of low manufacturing expenses, availability of skilled and cheap labour, lenient regulations laid by governments. In fact, governments are encouraging the use of biosimilars. For example, the government of India provides various necessary and regulatory procedures for the usage of biosimilars products.

Asia-Pacific Biosimilars Market was worth $0.78 billion in 2016 and estimated to be growing at a CAGR of 39%, to reach $4.05 billion by 2021.

Based on geography the Asia-Pacific market is segmented into various regions namely Japan, China, India and Australia.

India and China are estimated to grow the fastest. Other countries such as South Korea are also expected to record high growth over the next five years. India is one of the largest hubs for the biosimilar industry and observes a presence of over 30 leading firms that operate in the development of biosimilars, some of which include Dr Reddy’s Laboratories, Wockhardt, Lupin, Cipla, Avesthagen, Biocon, and Zydus Cadilla.

Some of the major players in the biosimilars market in Asia Pacific:

Middle East: The Middle East and Africa Biosimilars Market was worth $0.37 billion in 2016 and estimated to be growing at a CAGR of 32%, to reach $1.63 billion by 2021.

Biosimilars are rising as a standout amongst the most vital area in the medicinal services industry. With expanding social insurance costs, biosimilars are being looked upon as a moderate treatment alternative. Developing economies are watching far reaching development in biosimilars industry from requesting clinical necessities of therapeutics. Ascend in GDP and human services consumptions, and the interest for practical therapeutics arrangement has brought about the development of this market

Conclusion: Like most other markets, a competitive biologics market can offer benefits to consumers by lowering prices and enhancing quality. In addition, biosimilars have an unblemished safety track record in the E.U., where biosimilars have been competing against biologics since 2006. Biosimilars have also proved to have a notable impact on drug prices. In the E.U., where biosimilars are already competing with biologics, biosimilars are sold at a 30% discount compared to branded biologic drugs.

Though biosimilars industry face many challenges like Patent and Legal Issues, Production Bottlenecks, Pricing Issue, Regulatory issues and lack of awareness.

In spite of the approval of 21 biosimilars in Europe, only 18% of the physicians are aware of these similar versions of biologics. However bisimilar industry seems to have a bright future as an alternative to patent biologics.

References:

https://www.marketsandmarkets.com/PressReleases/global-biosimilars-product-market-worth-19.4-billion-by-2014.asp

https://www.omicsonline.org/open-access/biosimilar-drugs-market-future-trends-in-unitedstates-2153-2435-1000543.pdf

https://www.prnewswire.com/news-releases/global--usa-biosimilar-market-analysis-report-2015-2021-300134719.html

https://www.biosimilardevelopment.com/doc/biosimilars-market-europe-forecast-to-0001

https://www.biologicsblog.com/biosimilars-europe-2016-year-review-whats-ahead

http://www.marketdataforecast.com/market-reports/asia-pacific-biosimilars-market-1145/

https://www.medgadget.com/2017/11/asia-pacific-biosimilars-market-to-hold-a-share-worth-over-usd-4-05-billion-in-2021.html

https://en.wikipedia.org/wiki/Biosimilar

https://www.investopedia.com/news/top-4-challenges-biosimilar-growth-amgn-nvs/

Biosimilar 2018 Report

Meetings International successfully anchored its leading "World Biosimilars Conference" slated on August 20-21, 2018 at Chicago, USA.

Biosimilar 2018 is distinguished with the attendance of Editorial Board Members of supported Journals, Scientists, young and brilliant researchers, business delegates and talented student communities representing more than 25 countries, who made this conference rewarding and fecund.

Our International Meeting on World Biosimilars Conference was based on the theme “New Inventions in Biosimilars” which has encrusted the below

Scientific sessions:

Biosimilars- Hatch-Waxman Act & BPCI Act
Challenges in Developing Biosimilars
Current Developments in the Field of Biosimilars
Emerging Trends in Biosimilars
Cost Analysis of Biosimilars
Clinical Studies on Biosimilars
Innovative Approach for Biosimilars
Consequences of Brexit on Biosimilars
Biosimilars Market- Challenges & Prospects
Globalization of Biosimilars
Intellectual Property Rights
US-FDA Approved Biosimilars
Biosimilars Approved in Europe
Biosimilars in Cancer Therapy

The conference was initiated and embarked with an Opening Ceremony followed by a series of lectures delivered by members of the Keynote forum and Speakers. The peerless people who promulgated the theme with their exquisite talks were:

Sarfaraz K Niazi, Karyo Biologics LLC and Pharmaceutical Scientist Inc, USA
Ronald P Dudek, Lentigen Technology Inc., USA
José Carlos Ferreyra López, President, Instituto de Investigación e Innovación Farmacéutica, Mexico
Milind Antani, Nishith Desai Associates, India.
Joel I. Osorio, Chief Executive Officer / Founder, Regenerage, Mexico.
Rafiq Islam, Celerion Inc., USA
Roberto Valenti, DLA Piper, Italy
James Stout, BioVectra Inc, Canada.
James M Sulzberger, Downstream Purification Scientist, Bio Rad Laboratories, USA
William Rushton Process chromatography support scientist, Bio Rad Laboratories, United States.
Sandra Simic, Ewopharma, Croatia.
Yazan Shaban, Hikma Pharmaceuticals, Jordon
Aaron D Barzey, ADB Medical, UK
Ismaeil Saad, Theodore Bilharze research Institute, Egypt

Meetings International wishes to acknowledge with its deep sincere gratitude to all the supporters from the Editorial Board Members of our Open Access Journals, Keynote speakers, Honorable guests, Valuable speakers, Poster presenters, students, delegates and special thanks to our Exhibitor Mobius Analytics, Collaborator European Nanoscience and Nanotechnology Association (ENNA), Media Partners (Tabeeby, enliven, Kind Congress, Conferize, Classified 4 Free and Nature events directory) for their promotion to make this event a huge success.

For past conference website kindly follow this link:

https://www.meetingsint.com/conferences/biosimilar/2018

For more details about Biosimilar 2018,

Please Visit: https://www.meetingsint.com/conferences/biosimilar/2018

Highlights
Supporting Journals

Application of Nanotechnology in Biologic Drug Development
Biologics & Biosimilars: Analytical Strategies
Biologics Vs Biosimilars
Biosimilars Vs Bio-betters
Drug development for Rare Diseases
Generics and Biosimilars: Industrial Strategy and Market Analysis
Clinical Trials of Biologics & Biosimilars
GMP, GCP, QC & R&D
Sustainability of the Biologics & Biosimilar Medicines Sector
Novel Drug Delivery Technologies

Facebook

11 Organizing Committee Members

More...

12 Renowned Speakers

Media Partners & Collaborations

Media Partner

fgsg
tgh

Dear Eliza, Thank you for that wonderful opportunity given to share my experiences during the conference. I would like to place on record the smooth conduct of the conference. My appreciation goes a long way to Eliza for her timely communication and well advanced information disseminated processes. The presentation schedule and the time mentioned in the mail sent were also strictly followed. All the best. Regards Kalyani Kenneth Speaker | Psychiatry-2021
Kalyani Kenneth

Dear Laura, Thank you for giving me the opportunity to present my current work! I really enjoyed listening and connecting to a wider international scientist through this conference. And I am really looking forward for the physical conference next year! Best regards Sharmaine
Sharmaine Reintar

Many thanks Laura. It iş my plesure work with you
Pinar Kara

It was my pleasure to be a part of the conference. The talks were technically profound. Thank you once again.
Anupam Mukherjee

Thank you very much for the message. I am glad that the presented poster was appreciated. I'm also grateful for the certificate. Dispite my main work was the subject presented in the session, it would be a pleasure to participate in the webinars.
Ana Rita Domingues

Thank you for your appreciation. I love the support received from you and your admirable patience from invitation till the end of the conference. Thank you very much. I hope to participate in future conferences.
Munezza Khan

Am really grateful for you inviting me to this great event... Am thrilled to be part of this great team, I feel honored 😀😃😄🤝🏻
Aysha Haruna

The conference was arranged nicely through a Webex. I found the sessions interactive and informative. I am looking forward to join the next annual meeting of plant genomics in osaka, japan in april 2022.
Ruchika

Highly appreciate your quick response and I am grateful for all your help.
Dr. P T Sunderam

Informative and Innovative sessions
Michael Lacroix

Delightful event with a wonderful sessions
Mohamed Ebraheem Elmesserey

Very much grateful for this opportunity to share the innovative ideas
Mahmoud Metwaly Taha

It was really informative and excellent platform to share the research ideas
Raktima Chakrabarti

Wonderful experience
KHALED NASR ELDIN REYAD

Thank you very much for organizing this wonderful conference
JIMMY KAYASTHA

it was impressive and left me a very good memory.
VAISHALI SAMIR JOSHI

I learnt a lot from the conference and hope to attend the next conference
Deepak Mane

It was a nice and well-organized meeting! Thank you for all your efforts of having put it together.
Vladimir Startsev

The conference was exciting. I enjoyed so much meeting new colleagues at the venue. I would like to express my sincere gratitude to you for your assistance and opportunity. It was a good experience attending this conference.
Daniela Capdepon

It was great being a part of Surgery 2021
Hadi Nural

How much I appreciate your support, you and your job are meaningful. I always wish the best for you. Thank Laura a lot
Kevin Ton

Hats off to you and fellow organizers. Great opportunities for sharing and networking!
Karen Swanepoel

It was a pleasure to participate in this year’s meeting (even in webinar format due to the COVID-19 pandemic) and I hope the participants enjoyed my talk. There were some interesting talks taking place today and the whole experience was enjoyable like last year. Please rest assured that I will be happy to join next year’s meeting as well, hopefully with a physical presence.
Vasileios Fotopoulos

It was my pleasure to attend this conference. Thanks for your kind efforts.
Saeed Taheri

Thank you for your effort for having made "Pharmacology 2019 conference" wonderful success. Thank you again for that.
Ryong Nam Kim

Thanks for holding a nice conference.
Ramin Ataee

I enjoyed the conference. Italy will be a great place to have the next conference. I look forward to 2020 edition.
Paul Njiruh Nthakanio

I am very happy to make a seminar in the conference. If I have a chance to present my work in your conference, I would talk it in your conference in future.
Takayuki Momma

It was good to connect with a diverse group of scientists - thanks very much for the invite
Thomas P Brutnell

It was a nice experience for me to attend plant genomics conference in Osaka and meet researchers from different countries.
Behnam Derakhshani

It has been an excellent experience.Thank you a lot for this opportunity. I enjoyed it very much!
Julio Cesar Vega

I definitely would like to join your conference again. It was so great about everything. I think I would say great coordination and services.
Maryam Jenabi

Great experience being a part of this conference as a moderator
Soizic de Beaucorps

Amazing experience full of knowledge and meeting new people. Looking forward to being back
Thomas Frederick Hartley

Thanks a lot. It was an excellent event. Really enjoyed.
Umesh Prabhu

It was a pleasure and a great opportunity to be one of the Keynote speakers. I welcome the opportunity to speak at additional conferences in the future. Please keep my contact information for future consideration.
Sharon Nixon-Crenshaw

Thank you for assisting in my participation in a superbly organized Conference. I especially appreciate that you made a special session for me. And once again, sincerely thank you for inviting me to the Conference.
Albert Krashenyuk

Thank you for all your help for the meetings. It was for me a great experience to be in a kind and so scientific group.
Katia lollai

I enjoyed a lot thank you. I thank Meetings International for the quality of the event. All the speakers i had notice of were well prepared and highly motivated Compliments!
Dora Dragoni DÄ±vrak

Thank you for organizing the conference. It was nice to partake in the event.
Marcello Menapace

I enjoyed participating in the congress and thank you for your efforts to make it easy for participants. Please keep me in mind for future meetings.
Debendra Kumar Tripathy

It was a nice meet and we had a wonderful time in Paris Thank you once again for the arrangement. I would be interested in participating future meetings.
Prasanna Udupi Bidkar

Thank you so much for giving me a chance to my research presentation in your conference.
Seyedataollah montazam

I enjoyed being in the conference. Thanks for you excellent arrangement for my participation. Looking forward for next meetings.
Afaf El Ansary

The conference is very nice, Thank you so much for inviting me to your esteemed event.
Esmira Naftali

The conference was very good. I hope to attend similar meeting in future. Thank you .
Lia Monica Junie

I am indeed glad to acknowledge that for last two days during Optics-2018, International conference on Lasers, Optics and Photonics it was Successfully conducted and we had very fruitful discussions and interactions to make many great friends for life. Many Delegates had interactions with many famous Japanese University Professors and company Managers too for their future possibilities of R&D collaborations. I had arranges a session for such interactions while eating and discussing with relaxed environment and taking group pictures. The hospitality provided by your Organization Committee Members was excellent to help completing Conference Inauguration, all Keynote Speeches, Oral Presentations And Poster session had very high-quality research presentations in many advanced research areas such as Spectroscopy, Ultra high power Lasers, Fibers, Advances in stabilized high frequency mode-locked pulsed Fiber Lasers, MEMS, Optical Interconnects, Photonics and Advanced Optical Biomedical Imaging, THz and optical communications and Interconnects, theoretical and experimental research and so on from highly recognized Professors and Researchers in Japan and advanced institutions in many advanced countries.
Dr. Brahm Pal Singh

I wish to thanks you for my perfect time on conferense in Osaka. It was great experience for me.
Anton Podkopaev

I wish to thanks you for my perfect time on conferense in Osaka. It was great experience for me.
Dr. Anton Podkopaev

I would refer this organization future conferences to my colleagues and also love to join again in diabetes related events. More topics on diabetes should be there in future diabetes conferences.
Radia Boufermes

Thank you for the invitation and the opportunity to participate. It was very good.
Juliana Francisca Grossi Heleno

Thank you very much for the invitation and it was a great honor for me to join this conference. I had a great time.
Alkis Konstantinopoulos

It was a good event and got to make good friends out there.
Nur Ozel

Thank you so much. Really we appreciate the Congress, hope next time it will be longer. Everything was ok, the venue, colleagues, organizing team. Thank you and hope to meet soon in other Congress soon.
Sameh Samy Abdou

It was a great pleasure of mine to be there during the conference looking forward to joining your future conferences
Ahmed Halim Ayoub

The theme of the conference and the scientific panel are very interesting! I am looking excited to learn many new things on this innovative platform
Lisa mattheu

I would love to attend the Infectious Diseases 2019 conference. The hospitality, the renowned speakers, and the city are awesome. Looking forward to it!
Dr. Ianane Jireh Ramos canizares

Hello Daniel, Thank you for the invitation to the conference. It was an interesting experience. I am glad that my presentation was liked. Like the effects of my work. Stay in touch. Best Regards !
Aneta Zymon

Thank you to Daniel Raybin with Wound Care 2018 for allowing me to be the Keynote Speaker for the conference. Dr. Jeff Mayo and I met colleagues from other countries such as Poland and Ukraine that work in plastic medicine and surgery. We are excited to share our knowledge of wound care in the veterinary industry so that our human medicine counterparts can offer the same standardized care that we utilize in the US. Thank you to Regenlabs for sponsoring the event and Jorgensen Laboratories for providing us with a great sponsor to represent our mission.
Nicole LaForest

Dear Daniel! Thank you for the conference, for your accommodation and the opportunity to see the most romantic, mysterious, fabulous Amsterdam
Nadiia Nor

Congress was good, the quality of the presentations was good. The choice of Singapore as strategic headquarters has been good
Buonocore D

Thanks for your invitation. I enjoyed participating at he conference in Rome and am interested in participating again next year in Paris.
Daniel Benetti

Great experience!! Thanks a lot for the opportunity to speak.
Jose Carlos Ferreyra Lopez

Dear Julie, Many thanks to you as you offered me this opportunity to come and participate at this valuable event in Chicago. I think you are great professional and made huge efforts for the event in terms of organization, engaging speakers, etc. And also you have sense for people, act as empathic person what is very important for me. I was very happy and honored to be invited as a speaker at World Biosimilars Conference in terms to present company Ewopharma AG as business partner of different pharma companies in Central and Eastern Europe, especially company Biogen with its portfolio of biosimilars and share my commercial experience in launching biosimilars! I found the conference interested in terms you selected very qualitative speakers from different areas: innovation and science, manufacturing and commercialization. From my perspective, the most interesting topics were: Sarfaraz K Niazi: “Biosimilars: Why are they so widely misunderstood?” Ronald P Dudek: “The adapter CAR Platform: From antibody to CAR T cell therapeutic” Jose Carlos Ferreyra Lopez: “Market access barriers and market value in Mexican public sector for biosimilars” Milind Antani: “Similar biologics in India- Impact of regulations on business” Joel I Osorio: “RegenerAge System “ (So I will be very happy if you could share these mentioned presentations with me!). I can see more potential for further improvement to put 100% focus on Biosimilar topics and to attract more specialists/professionals to gather. It will be excellent if you could attract more speakers from Europe to share their experience. So please consider this option how to attract them in the future (if I got some nice ideas will share with you!).
Sandra Simic

Thanks for giving opportunity to share my research at 3d printing conference .I meet global experts and exchange our ideas.Two days conference are going very good ,workshop session,exhibition .I felt moved to contribute next year also..
Rajkumar Velu

It is wonderful conference of 3d printing & Bio printing in health care .participates are coming from world wide 3d printing & Bio printing experts .Workshop sessions is too good .
Lifeng Kang

• Good workshop session at conference with lots of discussion among audiences and speakers about the regulatory aspect of 3D printed medical devices. • Many of the topics were good and interesting. • It will be good if the organizer could have invited more participants as well as selecting the speakers based on proven and relevant track record. • It will be better if there are people who keep track of the time for each topic.
Albert Sutiono

Conference was superb. It was well conducted. I appreciate all the speakers, presenters and organizers. I am very proud to be part of this event.
Rajani singh

We had a very good session at cardiomersion in which we discuss about the integrated cardiomersion approach to the delivery of cardiovascular case. Thank you to all the speakers who came across the globe. Finally I would like to thank the organizers for making such a remarkable event.
Deepak Puri

I have been a part of this conference and I am very proud to see the conference very well organized and people are helping us and each other to present their case reports and research. Thank you very much to the organizers for making such great events
Suresh Vatsyayan

The event was very nice and I want to thank all the participants, presenters and the organizers. We hope in future we will have more events like this
Yuan Chen

The BABE conference was very interesting and lot of scientific sessions were covered and highlighted. Special thanks to the Organizing Members and the participants
Kateryna Zupanets

Conference was good, thanks for organising. I felt moved to contribute throughout, and felt that to a certain extent I acted as a moderator throughout the event .It is very happy for me.
Alexander M. Korsunsky

I want to express my graduate and thanks to you for all efforts you put to organize such a successful conference. For 2 days I enjoyed the company of brilliant and beautiful minds from all over the world. I had a great chance to exchange expercties with them and in large my horizons. I want to thank you again for organizing the International Conference of Petroleum Engineering 2018, Dubai, UAE and hope to meet you again very soon.
Essa Georges Lwisa

I enjoyed participating in the congress and thank you for your efforts to make it easy for participants. Please keep me in mind for future meetings relating to bariatric surgery, I would be interested in participating or being part of the organizing committee.
Peter Harris

Meetings International meetings are great way to receive way to receive other scientists in different parts of the world doing, These meetings provides the opportunity for you to work at latest concepts from different peoples also specifically it allows the opportunity to call to the new relationships when it resolves in future collaboration across the photolamps
Suzanne Tinsley

I enjoyed conference with Meetings International it is a mutal legitimate.It is always with first move which encourages scientists for practicing ability based practice It also gives lots of opportunity for discussions as well as collaborations in future
Dr. Marie Vazquez Morgan

We enjoyed the meeting so much. Wish you all success in the coming meetings.
Richa Jaiswal

It was a great experience for us to attend the conference. Had good interactions with speakers. Many thanks to you and Mr Peter Harris for giving us opportunity to participate and visit Japan as well. Wish to attend further conferences in future!
Kalpana Kulkarni

The first day was very good. It was meaningful to spend academic meeting. I thank you for your consideration.
Gagan Dhall

International meeting was good looking forward for next meetings.There can be more we can do because there is always scope for improve.
Suman Lata

Thanks for your greeting letter! We enjoyed the conference. Sure! We will meet again in 2019!
Dra Milagrosa C. S. Liu

First of all I would like to say many thanks to YOU and The Organization / Planning Committee, for I have been given the opportunity to join in this very Prestigious Event. I am also grateful to meet with researchers from other countries who have innovative research’s. Hopefully it could upgrade to my knowledge and more increases my interest in this field of science. Nice to join in this event I wish i could be join on the Traditional Medicine 2019.
Yunita Sari Pane

It was great experience for me. My talk was very much liked by all receipients at Osaka.
Mohammad Kamil

I am indeed glad to acknowledge that for last two days during Optics-2018, International conference on Lasers, Optics and Photonics it was Successfully conducted and we had very fruitful discussions and interactions to make many great friends for life. Many Delegates had interactions with many famous Japanese University Professors and company Managers too for their future possibilities of R&D collaborations. I had arranges a session for such interactions while eating and discussing with relaxed environment and taking group pictures. The hospitality provided by your Organization Committee Members was excellent to help completing Conference Inauguration, all Keynote Speeches, Oral Presentations And Poster session had very high-quality research presentations in many advanced research areas such as Spectroscopy, Ultra high power Lasers, Fibers, Advances in stabilized high frequency mode-locked pulsed Fiber Lasers, MEMS, Optical Interconnects, Photonics and Advanced Optical Biomedical Imaging, THz and optical communications and Interconnects, theoretical and experimental research and so on from highly recognized Professors and Researchers in Japan and advanced institutions in many advanced countries.
Dr. Brahm Pal Singh

I wish to thanks you for my perfect time on conferense in Osaka. It was great experience for me.
Dr. Anton Podkopaev

Interesting presentation & worthfull spirit of exchange of experience
Ippei Sakamaki

Thanks a lot we hade a great time and grest conference. We enjoyed the conference .
Chi-Ying Huang

I would like to express my gratitude for your engagement in preparation of the Cancer Therapy Summit 2018. It was a valuable experience.
Hong Qin

Conference was good. Thanks for your support and co operation.
GURUSAMY MARIAPPA

My active partecipation to the Toronto meeting is just over and motivated by it and by Joseph Ndisang who I met there, I'd like to ask and verify whether I could further collaborate more actively, with no expenses for it, within yr network with my long term scientific expertise and long background in the field of diabetes and also at the light of my previous experience with you over the last year.
Marco Songini

“ The organisation and coordination of the international conference of nanotechnology and nanoengineering was at an outstanding level, it was a great honour to participate in such phenomenal event “
Ahmed Abushomi

I also really appreciated all the scientific contact I made within all these participants - Think that in the future if you might request some help for that renewal activity, I might be helping your team of course (I have some suggestions for making better sort / type of presentation activities for invited speakers of course according to my experience in the field).
Jean-paul Lellouche

The conference sesions proceeded successfuly in a hot and friendly atmospher. I observed during the conference every delegate and speaker interacted wit each other and made friend. I am sure that the conference has become a scientific platform to exchange knowledge among the scientists from all over the world, and they wil conduct a new collaborations. During the conference, onsite organizers spent a great efford. I believe that the level and quality and reputation will increase year to year. Unexpected and unavoidable circumstances can occur at everywhere and every activation, and they can be solved easily. Hope to meet you and your team in another conference.
Osman Adiguzel

Thank you for your friendly mail. I enjoyed the conference with interesting speakers. I did not know anybody at the beginning but I found good companions during the conference.The hotel was good but it was located somewhat outside of Paris. Nevertheless, we had a good time. Anyway, thank you again for your invitation.
Nikolaus Stolterfoht

Thank you. Yes the conference was really interesting.
Adil Aghzar

Thank you! I also think that the event was very successful and very interesting. The variety of thematic session and possibility to meet experts from different fields of marine biology and aquaculture was the biggest advantage of the conference. However, it might be useful to attract more participants to next conference.
Magdalena Jakubowska

Thank you for your kind welcome and appreciated support during the appreciable meeting. Thank you for your kind offer to continue to cooperate to this interesting initiative and I am available to cooperate again in remote and to eventually attend the conference. Thank you and your colleagues and the scientific valuable people that attended the conference for your kind cooperation.
Gianluca Ragusa

Thank you for allowing me to participate in this event, I liked the organization and the people who participated, I made many friends too. Of course I would like to collaborate with you in organizing the next Aqua 2019 conference.
Alfredo Olivera Galvez

The meeting was a success with many experience professional.
Nyan Taw

A very thorough and well written set of points. It’s great that you took the time to put this together.
Feng Gao

Thank you for offering an unforgettable experience for all of us. We are honored to attend the conference. We are so happy and thanks a lot.
Stef Stienstra

Many thanks for your continuous support throughout the conference. It was the pleasure to participate and shared the findings at such high level meetings.
Pooja Jain

The conference was very enjoyable and I was honoured to be able to present my research at this prestigious event. The conference was particularly good for me as it is always important to keep up with the new developments
Glenda Gray

I had a wonderful time at the conference and learned so much from the presenters. Thank you kindly for putting this event together.
Marc HV Van Regenmortel

I had a great time in the conference, Everythings are OK, thank you .
Hsiao-Hui Chiu

Wonderful!! thank you for all the help you have done
Sharadha Ramesh

Thank you for your arrangement. Our team enjoyed the meeting so much. Wish you all success in the coming meetings!
CHAN Yui Fung

Surely we will maintain our relation in long run. If there is any opportunity for me to start my carrier being fresher and any guidance from you to me. It will be highly appreciated.
Monika kankarwal

I appreciate your polite contact. I enjoyed my first visit to Singapore. It was meaningful to spend academic meeting. I thank you for your consideration.
Kazue Sawami

Thank you for the email ,it was my sincere honor and pleasure to participate , many thanks for the invitation ,well organised conference, great hospitality ,well composed programme,interesting nursing topics, but not very large group size enough group size to be conducive to excellent discussions, I wish you all the success for your further conference
Hana Kadhom

Thank you for successful conference in Singapore. And thank you for giving me opportunity of oral presentation. It was very good experiences to me.
Hyun, Myung sun.

11^th World Congress on

Biosimilars and Biologics

Biosimilar 2019

Theme: Biosimilars Vs. Biologics: Does accessibility ensure efficiency?

11 Organizing Committee Members

12 Renowned Speakers

Markus Fido

Peter Hans Kalinka

Sandra Simic

Sabiruddin Mirza

Joel Garcia

MOHAMMAD HOJOUJ

Jose Carlos Ferreyra

Candida Fratazzi

Moustafa Magdy

Michel Mikhail

Aaron Barzey

Hareesh Parandhaman

Media Partners & Collaborations